Turkish Real-Life Atrial Fibrillation in Clinical Practice: 2-Year Clinical Outcomes of the TRAFFIC Study
| dc.contributor.author | Karabay, Can | |
| dc.contributor.author | Astarcioglu, Mehmet | |
| dc.contributor.author | Agca, Fahriye | |
| dc.contributor.author | Yilmaz, Ahmet | |
| dc.contributor.author | Akture, Gulsah | |
| dc.contributor.author | Aslan, Ahmet | |
| dc.contributor.author | Tanboga, Ibrahim | |
| dc.date.accessioned | 2026-07-01T11:39:37Z | |
| dc.date.available | 2026-07-01T11:39:37Z | |
| dc.date.issued | 2026 | |
| dc.department | Düzce Üniversitesi | |
| dc.description.abstract | Background: Atrial fibrillation (AF) is a major public health issue associated with thromboembolism and mortality. Real-world data from Tü rkiye are limited despite expanding use of non-vitamin K antagonist oral anticoagulants (NOACs). The Turkish Real Life Atrial Fibrillation in Clinical Practice (TRAFFIC) study aimed to characterize the demographic features, risk profiles, treatment patterns, and 2-year clinical outcomes of patients with non-valvular AF (NVAF) in Tü rkiye. Methods: TRAFFIC was a national, prospective, multicenter, observational registry enrolling 1659 NVAF patients from 36 centers with 6-monthly follow-up for 24 months. Baseline data included demographics, comorbidities, CHA2DS2-VASc, HAS-BLED, AF subtype, European Heart Rhythm Association (EHRA) score, and antithrombotictherapy. Outcomes were ischemic stroke/systemic embolism (SE), major bleeding, and all-cause mortality. Predictors of mortality were evaluated using adjusted Cox regression, and associations of risk scores were explored using univariate Cox models with restricted cubic splines. Results: Median age was 70 years, 48% female, with intermediate CHA2DS2-VASc (most 2-5) and low-to-intermediate HAS-BLED scores (most 0-2). Permanent AF wasthe most common subtype (48%). Antithrombotic therapy largely reflected risk profiles, with NOACs being the dominant treatment (65%). Over 2 years, all-cause mortality was 8.9%, ischemic stroke/SE 2.4%, and major bleeding 1.3%. In adjusted analysis, age, congestive heart failure, and diabetes mellitus were independent predictors of mortality. Both CHA2DS2-VASc and HAS-BLED scores showed threshold effects for mortality and thromboembolic risk but notfor bleeding. Conclusion: TRAFFIC provides contemporary Turkish NVAF data, showing lower event rates than historical cohorts. Outcomes are comparable with international registries; persistent mortality burden highlights the needforAF care beyond anticoagulation. | |
| dc.identifier.doi | 10.14744/AnatolJCardiol.2025.5751 | |
| dc.identifier.endpage | 123 | |
| dc.identifier.issn | 2149-2263 | |
| dc.identifier.issn | 2149-2271 | |
| dc.identifier.issue | 2 | |
| dc.identifier.orcid | 0000-0002-8389-5174 | |
| dc.identifier.orcid | 0000-0003-4546-9227 | |
| dc.identifier.orcid | 0000-0002-6991-5749 | |
| dc.identifier.orcid | 0000-0003-2455-8909 | |
| dc.identifier.pmid | 41459663 | |
| dc.identifier.scopus | 2-s2.0-105031054465 | |
| dc.identifier.scopusquality | Q3 | |
| dc.identifier.startpage | 116 | |
| dc.identifier.uri | https://doi.org/10.14744/AnatolJCardiol.2025.5751 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12684/23366 | |
| dc.identifier.volume | 30 | |
| dc.identifier.wos | WOS:001688515300009 | |
| dc.identifier.wosquality | Q3 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Kare Publ | |
| dc.relation.ispartof | Anatolian Journal of Cardiology | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WOS_20260623 | |
| dc.subject | [Keyword Not Available] | |
| dc.title | Turkish Real-Life Atrial Fibrillation in Clinical Practice: 2-Year Clinical Outcomes of the TRAFFIC Study | |
| dc.type | Article |












